462 related articles for article (PubMed ID: 19053881)
1. Targeting STAT3 in cancer: how successful are we?
Yue P; Turkson J
Expert Opin Investig Drugs; 2009 Jan; 18(1):45-56. PubMed ID: 19053881
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.
Masciocchi D; Gelain A; Villa S; Meneghetti F; Barlocco D
Future Med Chem; 2011 Apr; 3(5):567-97. PubMed ID: 21526897
[TBL] [Abstract][Full Text] [Related]
4. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
5. STAT proteins as novel targets for cancer drug discovery.
Turkson J
Expert Opin Ther Targets; 2004 Oct; 8(5):409-22. PubMed ID: 15469392
[TBL] [Abstract][Full Text] [Related]
6. STAT3 as a target for inducing apoptosis in solid and hematological tumors.
Al Zaid Siddiquee K; Turkson J
Cell Res; 2008 Feb; 18(2):254-67. PubMed ID: 18227858
[TBL] [Abstract][Full Text] [Related]
7. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
8. Revisiting STAT3 signalling in cancer: new and unexpected biological functions.
Yu H; Lee H; Herrmann A; Buettner R; Jove R
Nat Rev Cancer; 2014 Nov; 14(11):736-46. PubMed ID: 25342631
[TBL] [Abstract][Full Text] [Related]
9. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
Kim BH; Yi EH; Ye SK
Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.
Huang W; Dong Z; Chen Y; Wang F; Wang CJ; Peng H; He Y; Hangoc G; Pollok K; Sandusky G; Fu XY; Broxmeyer HE; Zhang ZY; Liu JY; Zhang JT
Oncogene; 2016 Feb; 35(6):783-92. PubMed ID: 26073084
[TBL] [Abstract][Full Text] [Related]
11. Signal transducer and activator of transcription 3 inhibitors: a patent review.
Page BD; Ball DP; Gunning PT
Expert Opin Ther Pat; 2011 Jan; 21(1):65-83. PubMed ID: 21114420
[TBL] [Abstract][Full Text] [Related]
12. SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Zhen H; Zhang X; Zhang L; Zhou M; Lu L; Wu L; He N; Wang J; Li R; Guo Y
Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):1098-1105. PubMed ID: 34169322
[TBL] [Abstract][Full Text] [Related]
13. Highlighted STAT3 as a potential drug target for cancer therapy.
Lee H; Jeong AJ; Ye SK
BMB Rep; 2019 Jul; 52(7):415-423. PubMed ID: 31186087
[TBL] [Abstract][Full Text] [Related]
14. Targeting transcription factor STAT3 for cancer prevention and therapy.
Chai EZ; Shanmugam MK; Arfuso F; Dharmarajan A; Wang C; Kumar AP; Samy RP; Lim LH; Wang L; Goh BC; Ahn KS; Hui KM; Sethi G
Pharmacol Ther; 2016 Jun; 162():86-97. PubMed ID: 26478441
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.
Mankan AK; Greten FR
Expert Opin Investig Drugs; 2011 Sep; 20(9):1263-75. PubMed ID: 21751940
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity.
Turkson J; Zhang S; Palmer J; Kay H; Stanko J; Mora LB; Sebti S; Yu H; Jove R
Mol Cancer Ther; 2004 Dec; 3(12):1533-42. PubMed ID: 15634646
[TBL] [Abstract][Full Text] [Related]
17. Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development.
Sgrignani J; Garofalo M; Matkovic M; Merulla J; Catapano CV; Cavalli A
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29843450
[TBL] [Abstract][Full Text] [Related]
18. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
Zhang L; Song Q; Zhang X; Li L; Xu X; Xu X; Li X; Wang Z; Lin Y; Li X; Li M; Su F; Wang X; Qiu P; Guan H; Tang Y; Xu W; Yang J; Zhao C
Invest New Drugs; 2020 Apr; 38(2):311-320. PubMed ID: 31087223
[TBL] [Abstract][Full Text] [Related]
19. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
20. STAT3 and metabolism: how many ways to use a single molecule?
Demaria M; Camporeale A; Poli V
Int J Cancer; 2014 Nov; 135(9):1997-2003. PubMed ID: 24500994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
